



Date: _____ Patient Name: _____ DOB: _____ Phone: _____ Last 4 SSN#: _____
 Patient Address: _____ Insurance Name & ID#: _____ Male ☐ Female ☐
 Referral Contact Name & Number: _____ Insurance Name & ID#: _____

Select Applicable Diagnosis and Include Recent Visit Notes and Diagnosis Specific Supporting Clinical Noted:

Immunology (ICD Codes)

- ☐ **Common Variable Immunodeficiency (D83.9)** Documented hx recurrent infections, low total pre-treatment IgG level, pre/post pneumo titers within 4-8 wks showing poor polysaccharide vaccine response
- ☐ **IgG Subclass Deficiency (D80.3)** Documented hx recurrent infections, one or more low pre-treatment IgG subclasses (IgG1, IgG2, IgG3, IgG4), pre/post pneumo titers within 4-8 wks showing poor polysaccharide vaccine response
- ☐ **Specific Antibody Deficiency (D80.6)** Documented dx and hx recurrent infections, Normal quantitative Ig levels, pre/post pneumo titers within 4-8 wks showing poor polysaccharide vaccine response
- ☐ **Severe Combined Immunodeficiency (D81.9)** Documented dx confirmed by genetic or molecular testing, pre-treatment low IgG level, very low/absent # T cells
- ☐ **Agammaglobulinemia (D80.0)** Documented dx confirmed by genetic or molecular testing, pre-treatment low IgG level, very low or absent number T cells
- ☐ **Nonfamilial Hypogammaglobulinemia (D80.1)** Documented hx recurrent infections, pre-treatment low IgG level (usually secondary or acquired)

Dermatology/Rheumatology (ICD Codes)

- ☐ **Pemphigus Vulgaris (L10.0)** Dx confirmed by biopsy and pathology report, hx rapidly progressing, extensive or debilitating condition and failed standard treatments (corticosteroids, immunosuppressive agents)
- ☐ **Dermatomyositis (M33.90)/Polymyositis (M06.9)** Documented dx, evidence of failed first line treatments (corticosteroids or immunosuppressants, testing (elevated muscle enzymes, muscle biopsy, skin biopsy)
- ☐ **Stiff Persons Syndrome (G25.8)** Documented dx and hx of first line treatments, anti-GAD antibody testing

Neurology (ICD Codes)

- ☐ **Chronic Inflammatory Demyelinating Polyneuropathy (G61.81)** Documented dx, progressive neurological symptoms, Electromyogram/Nerve Conduction (EMG/NCS), CSF (if available)
- ☐ **Multifocal Motor Neuropathy (G61.82)** Documented dx & hx, Electromyogram/Nerve Conduction (EMG/NCS)
- ☐ **Guillain-Barre Syndrome (G61.0)** Documented dx & hx of illness
- ☐ **Myasthenia Gravis (G70.0/G70.01)** Documented dx & worsening symptoms, + acetylcholine receptor (AChR) abs
- ☐ **Multiple Sclerosis (G35)** Documented dx of relapsing-remitting MS and previous treatments, diagnostic testing (ex. Neuro exam, MRI, +CSF study)

Transplant (ICD Codes)

- ☐ **Bone Marrow Transplant/Stem Cell Transplant Recipients (Z94.81/Z94.84)** Documented hx infection, date of Tx, pre-treatment low total IgG level
- ☐ **Solid Organ Transplant (Z94.____)** Documented dx & hx including indication for IVIG:
- ☐ Pre-transplant: high panel reactive antibody to human leukocyte antigens (HLA) (T86.91)
 - ☐ Post-transplant: Graft vs Host Disease (D89.810)
 - ☐ Post-transplant: recipients at risk for CMV (T86.0)
 - ☐ Post-transplant: treatment for antibody mediated rejection (T86.11)

Other (ICD Codes)

- ☐ **B-cell Chronic Lymphocytic Leukemia (C91.11)** Documented hx recurrent infections and date of Tx, pre-treatment low IgG level
- ☐ _____

Detailed Written Orders:

Height: _____ ☐ inches ☐ cm **Weight:** _____ ☐ lbs ☐ kg

Allergies: _____

☐ **IVIG** (pharmacist to brand) ☐ **SCIG** (pharmacist to brand)

☐ **Gamunex-C (J1561)** ☐ **Hizentra (J1559)**

☐ **Gammagard (J1569)** ☐ **Xembify (J1558)**

☐ **Privigen (J1459)** ☐ **HyQvia(J1575)**

☐ **Panzyga (J1599)** ☐ **Cutaquig(J3590)**

☐ **Alyglo (J1552)**

☐ _____ (other) ☐ _____ (other)

Dose: _____

Frequency: _____ **Duration:** _____

☐ **Pharmacist to dose**

Premedication: ☐ Diphenhydramine 25mg PO ☐ Acetaminophen 650mg PO

☐ **Hydration:** _____

Other: _____

☐ **Pharmacy OK to Substitute Brand when Insurance Dictates**

First Lifetime Dose: Yes: ☐ IgA level: _____ N/A: ☐

No: ☐ Previous Brands: _____

Date of Last Dose: _____ Next Dose Due: _____

Lab Orders: _____

Fax Lab Results To: _____

Ancillary orders will include:

Skilled Nursing Visits to administer (IVIG) and/or teach (SCIG) Infusions NaCl 0.9% 5-10ml IV before and after infusion for peripheral access and PRN Heparin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN All infusion supplies necessary to administer the medication Anaphylaxis Kit

☐ **IV E0781 Pump, A4221 Cath Supplies, A4222 Pump Supplies** ☐ **SQ K0552 Pump, A4221 Cath Supplies, A4222 Pump Supplies**

By signing below, I certify that above therapy is medically necessary. Prescriber's Signature (SIGN BELOW)

By signing this form & utilizing our services, I am also authorizing ContinuumRx to serve as my prior authorization agent with medical & pharmacy insurance providers.

Physician Signature: _____ Date: _____

Name: (Please print) Phone: _____ NPI #: _____

Phone Orders Received From: _____ Date/Time: _____

Fax: _____

Referral Checklist:

- ☐ Patient Demographics
- ☐ Copy Insurance Card
- ☐ Signed Orders Including Date, Dose, Freq, Duration
- ☐ Office/Hospital Visit Notes (within 3-6 months)
- ☐ Clinical Supporting Dx
- ☐ Pertinent Labs & Testing
- ☐ Tried & Failed Therapies

Legal Notice: The prescriber is to comply with their state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber. The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the recipient named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. This prescription may be filled out at a pharmacy of the patient's choice.